Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACABNASDAQ:INMBNASDAQ:NVCTNASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACABAtlantic Coastal Acquisition Corp. II$5.77-47.1%$8.44$5.75▼$13.00$47.14M0.019,443 shs162,400 shsINMBINmune Bio$7.70-2.8%$7.53$4.32▼$10.50$176.98M1.55287,514 shs593,330 shsNVCTNuvectis Pharma$8.41-4.8%$9.31$4.44▼$11.80$175.72M-0.16129,454 shs122,453 shsVYGRVoyager Therapeutics$3.30-8.3%$3.26$2.65▼$9.55$182.61M0.82477,276 shs913,503 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACABAtlantic Coastal Acquisition Corp. II0.00%0.00%0.00%0.00%-48.25%INMBINmune Bio-2.78%+1.05%+3.63%-3.14%-12.00%NVCTNuvectis Pharma-4.76%-4.97%-8.98%-4.97%+26.47%VYGRVoyager Therapeutics-8.33%-6.78%+3.45%-15.38%-61.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACABAtlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/AN/AN/AN/AINMBINmune Bio2.0408 of 5 stars3.60.00.00.03.21.70.6NVCTNuvectis Pharma2.9463 of 5 stars3.50.00.00.03.35.00.6VYGRVoyager Therapeutics4.4077 of 5 stars3.61.00.04.63.21.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACABAtlantic Coastal Acquisition Corp. II 0.00N/AN/AN/AINMBINmune Bio 3.17Buy$22.80196.10% UpsideNVCTNuvectis Pharma 3.00Buy$17.00102.14% UpsideVYGRVoyager Therapeutics 3.13Buy$13.39305.76% UpsideCurrent Analyst Ratings BreakdownLatest ACAB, VYGR, INMB, and NVCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $15.004/8/2025VYGRVoyager TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.004/2/2025NVCTNuvectis PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$17.003/17/2025NVCTNuvectis PharmaLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACABAtlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/AN/AINMBINmune Bio$50K3,539.54N/AN/A$2.07 per share3.72NVCTNuvectis PharmaN/AN/AN/AN/A$0.70 per shareN/AVYGRVoyager Therapeutics$66.96M2.73$2.34 per share1.41$5.37 per share0.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACABAtlantic Coastal Acquisition Corp. IIN/AN/A0.00∞N/AN/AN/AN/AN/AINMBINmune Bio-$30.01M-$1.93N/AN/AN/AN/A-117.48%-78.96%7/30/2025 (Estimated)NVCTNuvectis Pharma-$22.26M-$1.13N/AN/AN/AN/A-155.80%-104.02%8/5/2025 (Estimated)VYGRVoyager Therapeutics$132.33M-$1.464.65N/AN/A15.80%8.33%6.15%8/5/2025 (Estimated)Latest ACAB, VYGR, INMB, and NVCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025INMBINmune Bio-$0.43-$0.43N/A-$0.43N/A$0.05 million5/6/2025Q1 2025NVCTNuvectis Pharma-$0.30-$0.27+$0.03-$0.27N/AN/A5/6/2025Q1 2025VYGRVoyager Therapeutics-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 million3/27/2025Q4 2024INMBINmune Bio-$0.54-$0.40+$0.14-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACABAtlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACABAtlantic Coastal Acquisition Corp. IIN/AN/AN/AINMBINmune BioN/A2.592.59NVCTNuvectis PharmaN/A2.742.74VYGRVoyager TherapeuticsN/A8.458.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACABAtlantic Coastal Acquisition Corp. II23.30%INMBINmune Bio12.72%NVCTNuvectis Pharma96.77%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipACABAtlantic Coastal Acquisition Corp. II91.19%INMBINmune Bio35.20%NVCTNuvectis Pharma30.52%VYGRVoyager Therapeutics6.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACABAtlantic Coastal Acquisition Corp. II48.17 million720,000Not OptionableINMBINmune Bio1022.98 million14.37 millionOptionableNVCTNuvectis Pharma820.89 million12.41 millionNot OptionableVYGRVoyager Therapeutics10055.34 million52.15 millionOptionableACAB, VYGR, INMB, and NVCT HeadlinesRecent News About These CompaniesSpace Tech Ventures Surge: Voyager's IPO Success and Starlink's Swiss ExpansionJune 12 at 12:08 PM | devdiscourse.comVoyager Technologies Rises in Debut, Signaling Improving IPO MarketJune 12 at 7:07 AM | msn.comCantor Fitzgerald Estimates VYGR FY2026 EarningsJune 12 at 2:23 AM | americanbankingnews.comVoyager soars 82% on first day of trading as defense tech boomsJune 12 at 2:06 AM | msn.comInvestor demand for Voyager’s stock keeps growing, despite a mixed history for space-tech IPOsJune 11 at 9:05 PM | msn.comVoyager Technologies' Shares More Than Double in NYSE DebutJune 11 at 4:04 PM | marketwatch.comVoyager Technologies Shares Soar In Market DebutJune 11 at 4:04 PM | news.crunchbase.comSpace tech firm Voyager valued at $3.8 billion as shares surge in NYSE debutJune 11 at 4:04 PM | aol.comVoyager raises $383 million from upsized IPOJune 11 at 4:04 PM | spacenews.comSpace and defense tech firm Voyager raises $382.8 million in IPOJune 11 at 4:04 PM | fastcompany.comVoyager Technologies Valued at $3.8 Billion in Stellar NYSE DebutJune 11 at 4:04 PM | msn.comVoyager Technologies’ IPO shows investors are still hot on space stocks, despite a mixed historyJune 11 at 4:04 PM | marketwatch.comVoyager Announces Pricing of Initial Public OfferingJune 10, 2025 | bakersfield.comBrokers Issue Forecasts for VYGR FY2026 EarningsJune 10, 2025 | marketbeat.comVoyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceJune 10, 2025 | globenewswire.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Recommendation of "Buy" by AnalystsJune 10, 2025 | americanbankingnews.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of "Buy" from AnalystsJune 10, 2025 | marketbeat.comVoyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade)June 7, 2025 | seekingalpha.comVoyager Technologies, Inc. Announces Launch of Initial Public OfferingJune 3, 2025 | finanznachrichten.deSpace Firm Voyager Technologies Seeks $1.6 Billion Valuation in IPOJune 2, 2025 | theinformation.com2001: A Space Odyssey's balletic waltz to be beamed to Voyager 1May 27, 2025 | newatlas.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACAB, VYGR, INMB, and NVCT Company DescriptionsAtlantic Coastal Acquisition Corp. II NASDAQ:ACABAtlantic Coastal Acquisition Corp. II does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in financial services industry and mobility sector. The company was incorporated in 2021 and is based in New York, New York. Atlantic Coastal Acquisition Corp. II is a subsidiary of Atlantic Coastal Acquisition Management II LLC.INmune Bio NASDAQ:INMB$7.70 -0.22 (-2.78%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$7.70 0.00 (0.00%) As of 06/13/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Nuvectis Pharma NASDAQ:NVCT$8.41 -0.42 (-4.76%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$8.32 -0.09 (-1.07%) As of 06/13/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Voyager Therapeutics NASDAQ:VYGR$3.30 -0.30 (-8.33%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.36 +0.06 (+1.67%) As of 06/13/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
